MAIA Biotechnology, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Nature of Business and Summary of Significant Accounting Policies - Additional Information (Details)

Nature of Business and Summary of Significant Accounting Policies - Additional Information (Details)			1 Months Ended	2 Months Ended	3 Months Ended	9 Months Ended
	Aug. 03, 2022 USD ($) $ / shares shares	Aug. 01, 2022 USD ($) $ / shares shares	May 31, 2022 USD ($) $ / shares shares	Feb. 28, 2022 USD ($) $ / shares shares	Sep. 30, 2022 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($) shares	Dec. 31, 2021 USD ($)	Aug. 12, 2021	Jul. 31, 2021
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
State of incorporation						DE
Date of incorporation						Aug. 03, 2018
Common stock, conversion description						minority stockholder of THIO received one share of MAIA common stock for each share of THIO common stock owned prior to the merger.
Common stock, conversion ratio						1
Working capital					$ 12,323,572	$ 12,323,572
Accumulated deficit					(39,090,204)	(39,090,204)		$ (28,437,993)
Cash					14,063,642	14,063,642		10,574,292
Current liabilities					2,456,293	2,456,293
Revenues						0
Number of common stock sold \| shares			11,111	263,729
Sale of common stock, price per share \| $ / shares			$ 9	$ 9
Gross proceeds from sale of common stock	$ 9,100,000		$ 99,999	$ 2,373,561		2,473,560	$ 5,366,170
Gross proceeds from initial public offering						11,500,000
Cash equivalents					0	$ 0		$ 0
IPO
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Number of common stock sold \| shares		2,000,000
Sale of common stock, price per share \| $ / shares		$ 5
Issuance of common shares					$ 8,750,095
Gross proceeds from initial public offering		$ 10,000,000
Overallotment Option
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Number of common stock sold \| shares	300,000
Sale of common stock, price per share \| $ / shares	$ 5
Gross proceeds from initial public offering	$ 1,500,000
Offering and Overallotment
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Cash issuance cost, net	2,406,170
Issuance of common shares	$ 9,093,830
MAIA Biotechnology, Inc. \| THIO Therapeutics, Inc.
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Ownership percentage by parent									93.30%
Minority stockholder ownership percentage									6.70%
MAIA Biotechnology, Inc. \| MAIA Drug Development Corporation
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Ownership percentage by parent										100.00%
DGD Pharmaceuticals Corporation
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
State of incorporation						DE
Date of incorporation						Apr. 01, 2019
MAIA Drug Development Corporation
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
State of incorporation						TX
Date of incorporation						Sep. 10, 2018
DGD or THIO
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Number of common stock sold \| shares							0